Probiotics used in human studies

Journal of Clinical Gastroenterology

Volumn 39, Issue 6, 2005, Pages 469-484

  Montrose, David C ^a   Floch, Martin H ^b  

^a UNIVERSITY OF CONNECTICUT HEALTH CENTER   (United States)

^b YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Bifidobacteria; Lactobacillus; Probiotics; Saccharomyces; Supplements

Indexed keywords

AMOXICILLIN; ANTIBIOTIC AGENT; CEFPODOXIME PROXETIL; CEPHALOSPORIN; CLARITHROMYCIN; ERYTHROMYCIN; ESTRIOL; GLUCOSE; LACTOSE; LACTULOSE; MESALAZINE; METRONIDAZOLE; PREDNISOLONE; PREDNISONE; PROBIOTIC AGENT; RABEPRAZOLE; REBEPRAZOLE; TINIDAZOLE; TRICHOMONIASIS VACCINE; UNCLASSIFIED DRUG; VANCOMYCIN;

ACUTE DIARRHEA; ALLERGY; AMEBIASIS; ASTHMA; ATOPIC DERMATITIS; BACTERIAL INFECTION; BIFIDOBACTERIACEAE; BLADDER CANCER; CANCER RECURRENCE; CARCINOGENESIS; CARDIOVASCULAR DISEASE; CHRONIC DIARRHEA; CLINICAL TRIAL; COLON DIVERTICULOSIS; CONSTIPATION; CRITICAL ILLNESS; CROHN DISEASE; CYSTIC FIBROSIS; DENTAL CARIES; DIARRHEA; DRUG FORMULATION; DRUG MECHANISM; ECZEMA; ENTEROCOCCUS; ESCHERICHIA; GASTRITIS; GASTROENTERITIS; GASTROINTESTINAL DISEASE; GASTROINTESTINAL INFECTION; HELICOBACTER INFECTION; HEPATIC ENCEPHALOPATHY; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTENSION; ILEITIS; INFANTILE DIARRHEA; IRRITABLE COLON; KIDNEY FAILURE; LACTOBACILLUS; LACTOBACILLUS ACIDOPHILUS; LACTOCOCCUS; LACTOSE INTOLERANCE; LEUCONOSTOC; LOW BIRTH WEIGHT; NEPHROLITHIASIS; PANCREATITIS; POSTOPERATIVE INFECTION; PREMENSTRUAL SYNDROME; PRIORITY JOURNAL; PROPIONIBACTERIACEAE; RESPIRATORY TRACT INFECTION; REVIEW; RHEUMATOID ARTHRITIS; SACCHAROMYCES; SEPSIS; STREPTOCOCCUS; TRAVELLER DIARRHEA; ULCERATIVE COLITIS; URINARY TRACT INFECTION; VAGINA CANDIDIASIS; VAGINITIS; XEROSIS;

CLINICAL TRIALS; GASTROINTESTINAL DISEASES; HUMANS; PROBIOTICS;

EID: 20844460798     PISSN: 01920790     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.mcg.0000165649.32371.71     Document Type: Review

References (191)

1. Macfarlane GT, Cummings JH. Probiotics and prebiotics: can regulating the activities of intestinal bacteria benefit health? BMJ. 1999;318: 999-1003.
2. Metchnikoff E. The Prolongation of Life: Optimistic Studies. London: Butterworth-Heinemann, 1907.
3. Guandalini S, Pensebene L, Zikri MA, et al. Lactobacillus GG administered in oral rehydration solution to children with acute diarrhea: a multicenter European trial. J Pediatr Gastroenterol Nutr. 2000;30: 54-60.
4. Huang JS, Bousevaros A, Lee JW, et al. Efficacy of probiotic use in acute diarrhea in children: a meta-analysis. Dig Dis Sci. 2002;47: 2625-2634.
5. Floch MH. Prebiotics, probiotics and dietary fiber. In: Buchman A, ed. Clinical Nutrition: A Guide for Gastroenterologists. Thorofare, NJ: Slack, (in press).
6. Gionchetti P, Rizzello F, Venturi A, et al. Oral bacteriotherapy as maintenance treatment in patients with chronic pouchitis: a double-blind, placebo-controlled trial. Gastroenterology. 2000;119:305-309.
7. PUBMED [database online]. Bethesda, MD: U.S. National Library of Medicine; 2004. Updated 27, 2004.
8. Hilton E, Isenberg HD, Alperstein P, et al. Ingestion of yogurt containing Lactobacillus acidophilus as prophylaxis for candidal vaginitis. Ann Intern Med. 1992;116:353-357.
9. Xiao SD, Zhang Z, Lu H, et al. Multicenter, randomized, controlled trial of heat-killed Lactobacillus acidophilus LB in patients with chronic diarrhea. Adv Ther. 2003;20:253-260.
10. Swanson KS, Grieshop CM, Flickinger EA, et al. Fructooligosaccharides and Lactobacillus acidophilus modify bowel function and protein catabolites excreted by healthy humans. J Nutr. 2002;132:3042-3050.
11. Saran S, Gopalan S, Krishna TP. Use of fermented foods to combat stunting and failure to thrive. Nutrition. 2002;18:393-396.
12. Williams AB, Yu C, Tashima K, et al. Evaluation of two self-care treatments for prevention of vaginal candidiasis in women with HIV J Assoc Nurses AIDS Care. 2001;12:51-57.
13. Anderson JW, Gilliland SE. Effect of fermented milk (yogurt) containing Lactobacillus acidophilus L1 on serum cholesterol in hypercholesterolemic humans. J Am Coll Nutr. 1999;18:43-50.
14. Simakachorn N, Pichaipat V, Rithipornpaisarn P, et al. Clinical evaluation of the addition of lyophilized, heat-killed Lactobacillus acidophilus LB to oral rehydration therapy in the treatment of acute diarrhea in children. J Pediatr Gastroenterol Nutr. 2000;30:68-72.
15. Saltzman JR, Russell RM, Golner B, et al. A randomized trial of Lactobacillus acidophilus BG2FO4 to treat lactose intolerance. Am J Clin Nutr. 1999;69:140-146.
16. Schaafsma G, Meuling WJ, van Dokkum W, et al. Effects of a milk product, fermented by Lactobacillus acidophilus and with fructooligosaccharides added, on blood lipids in male volunteers. Eur J Clin Nutr. 1998;52:436-440.
17. Mustapha A, Jiang T, Savaiano DA. Improvement of lactose digestion by humans following ingestion of unfermented acidophilus milk: influence of bile sensitivity, lactose transport, and acid tolerance of Lactobacillus acidophilus. J Dairy Sci. 1997;80:1537-1545.
18. Parent D, Bossens M, Bayot D, et al. Therapy of bacterial vaginosis using exogenously-applied Lactobacilli acidophili and a low dose of estriol: a placebo-controlled multicentric clinical trial. Arzneimittelforschung. 1996;46:68-73.
19. Hallen A, Jarstrand C, Pahlson C. Treatment of bacterial vaginosis with lactobacilli. Sex Transm Dis. 1992;19:146-148.
20. Simenhoff ML, Dunn SR, Zollner GP, et al. Biomodulation of the toxic and nutritional effects of small bowel bacterial overgrowth in end-stage kidney disease using freeze-dried Lactobacillus acidophilus. Miner Electrolyte Metab. 1996;22:92-96.
21. Katelaris PH, Salam I, Farthing MJ. Lactobacilli to prevent traveler's diarrhea? N Engl J Med. 1995;333:1360-1361.
22. Pattman RS, Sankar KN, Watson PG, et al. An audit of Gynatren (a Lactobacillus acidophilus lyophilisate) vaccination in women with recurrent bacterial vaginosis. Int J STD AIDS. 1994;5:299.
23. Salminen E, Elomaa I, Minkkinen J, et al. Preservation of intestinal integrity during radiotherapy using live Lactobacillus acidophilus cultures. Clin Radiol. 1988;39:435-437.
24. Shalev E, Battino S, Weiner E, et al. Ingestion of yogurt containing Lactobacillus acidophilus compared with pasteurized yogurt as prophylaxis for recurrent candidal vaginitis and bacterial vaginosis. Arch Fam Med. 1996;5:593-596.
25. Canducci F, Annuzzi A, Cremonini F, et al. A lyophilized and inactivated culture of Lactobacillus acidophilus increases Helicobacter pylori eradication rates. Aliment Pharmacol Ther. 2000;14:1625-1629.
26. Schiffrin EJ, Rochat F, Link-Amster H, et al. Immunomodulation of human blood cells following the ingestion of lactic acid bacteria. J Dairy Sci. 1995;78:491-497.
27. Spanhaak S, Havenaar R, Schaafsma G. The effect of consumption of milk fermented by Lactobacillus casei strain Shirota on the intestinal microflora and immune parameters in humans. Eur J Clin Nutr. 1998;52: 899-907.
28. Koebnick C, Wagner I, Leitzmann P, et al. Probiotic beverage containing Lactobacillus casei Shirota improves gastrointestinal symptoms in patients with chronic constipation. Can J Gastroenterol. 2003;17:655-659.
29. Cats A, Kuipers EJ, Bosschaert MA, et al. Effect of frequent consumption of a Lactobacillus casei-containing milk drink in Helicobacter pylori-colonized subjects. Aliment Pharmacol Ther. 2003;17: 429-435.
30. Guerin-Danan C, Chabanet C, Pedone C, et al. Milk fermented with yogurt cultures and Lactobacillus casei compared with yogurt and gelled milk: influence on intestinal microflora in healthy infants. Am J Clin Nutr: 1998;67:111-117.
31. Turchet P, Laurenzano M, Auboiron S, et al. J Nutr Health Effect of fermented milk containing the probiotic Lactobacillus casei DN-114001 on winter infections in free-living elderly subjects: a randomised, controlled pilot study. Aging. 2003;7:75-77.
32. Pedone CA, Bernabeu AO, Postaire ER, et al. The effect of supplementation with milk fermented by Lactobacillus casei (strain DN-114 001) on acute diarrhoea in children attending day care centres. Int J Clin Pract. 1999;53:179-184.
33. Aso Y, Akaza H, Kotake T, et al. Preventive effect of a Lactobacillus casei preparation on the recurrence of superficial bladder cancer in a double-blind trial: the BLP Study Group. Eur Urol. 1995;27:104-109.
34. Baerheim A, Larsen E, Digranes A. Vaginal application of lactobacilli in the prophylaxis of recurrent lower urinary tract infection in women. Scand J Prim Health Care. 1994;12:239-243.
35. Nobaek S, Johansson M-L, Molin G, et al. Alteration of intestinal microflora is associated with reduction in abdominal bloating and pain in patients with irritable bowel syndrome. Am J Gastroenterol. 2000;95: 1231-1238.
36. Wullt M, Hagslatt ML, Odenholt I. Lactobacillus plantarum 299v for the treatment of recurrent Clostridium difficile-associated diarrhoea: a double-blind, placebo-controlled trial. Scand J Infect Dis. 2003;35:365-367.
37. Goossens D, Jonkers D, Russel M, et al. The effect of Lactobacillus plantarum 299v on the bacterial composition and metabolic activity in faeces of healthy volunteers: a placebo-controlled study on the onset and duration of effects. Aliment Pharmacol Ther. 2003;18:495-505.
38. Sen S, Mullan MM, Parker TJ, et al. Effect of Lactobacillus plantarum 299v on colonic fermentation and symptoms of irritable bowel syndrome. Dig Dis Sci. 2002;47:2615-2620.
39. Naruszewicz M, Johansson ML, Zapolska-Downar D, et al. Effect of Lactobacillus plantarum 299v on cardiovascular disease risk factors in smokers. Am J Clin Nutr. 2002;76:1249-1255.
40. McNaught CE, Woodcock NP, MacFie J, et al. A prospective randomised study of the probiotic Lactobacillus plantarum 299V on indices of gut barrier function in elective surgical patients. Gut. 2002;51:827-831.
41. Rayes N, Seehofer D, Hansen S, et al. Early enteral supply of lactobacillus and fiber versus selective bowel decontamination: a controlled trial in liver transplant recipients. Transplantation. 2002;74: 123-127.
42. Niedzielin K, Kordecki H, Birkenfeld B. A controlled, double-blind, randomized study on the efficacy of Lactobacillus plantarum 299V in patients with irritable bowel syndrome. Eur J Gastroenterol Hepatol. 2001;13:1143-1147.
43. Olah A, Belagyi T, Issekutz A, et al. Randomized clinical trial of specific lactobacillus and fibre supplement to early enteral nutrition in patients with acute pancreatitis. Br J Surg. 2002;89:1103-1107.
44. Cunningham-Rundles S, Ahrne S, Bengmark S, et al. Probiotics and immune response. Am J Gastroenterol. 2000;95(suppl 1):22-25.
45. Johansson ML, Nobaek S, Berggren A, et al. Survival of Lactobacillus plantarum DSM 9843 (299v), and effect on the short-chain fatty acid content of faeces after ingestion of a rose-hip drink with fermented oats. Int J Food Microbiol. 1998;42:29-38.
46. Bukowska H, Pieczul-Mroz J, Jastrzebska M, et al. Decrease in fibrinogen and LDL-cholesterol levels upon supplementation of diet with Lactobacillus plantarum in subjects with moderately elevated cholesterol. Atherosclerosis. 1998;137:437-438.
47. Rembacken BJ, Snelling AM, Hawkey PM, et al. Non-pathogenic Escherichia coli versus mesalazine for the treatment of ulcerative colitis: a randomized trial. Lancet. 1999;354:635-639.
48. Fric P, Zavoral M. The effect of non-pathogenic Escherichia coli in symptomatic uncomplicated diverticular disease of the colon. Eur J Gastroenterol Hepatol. 2003;15:313-315.
49. Cukrowska B, LodInova-ZadnIkova R, Enders C, et al. Specific proliferative and antibody responses of premature infants to intestinal colonization with nonpathogenic probiotic E. coli strain Nissle 1917. Scand J Immunol. 2002;55:204-209.
50. Malchow HA. Crohn's disease and Escherichia coli: a new approach in therapy to maintain remission of colonic Crohn's disease? J Clin Gastroenterol. 1997;25:653-658.
51. Kruis W, Schutz E, Fric P, et al. Double-blind comparison of an oral Escherichia coli preparation and mesalazine in maintaining remission of ulcerative colitis. Aliment Pharmacol Ther. 1997;11:853-858.
52. Lodinova-Zadnikova R, Sonnenborn U. Effect of preventive administration of a nonpathogenic Escherichia coli strain on the colonization of the intestine with microbial pathogens in newborn infants. Biol Neonate. 1997;71:224-232.
53. Shornikova A-V, Casas I, Isolauri E, et al. Lactobacillus reuteri as a therapeutic agent in acute diarrhea in young children. J Pediatr Gastroenterol Nutr. 1997;24:399-404.
54. Ouwehand AC, Lagstrom H, Suomalainen T, et al. Effect of probiotics on constipation, fecal azoreductase activity and fecal mucin content in the elderly. Ann Nutr Metab. 2002;46:159-162.
55. Wolf BW, Wheeler KB, Ataya DG, et al. Safety and tolerance of Lactobacillus reuteri supplementation to a population infected with the human immunodeficiency virus. Food Chem Toxicol. 1998;36:1085-1094.
56. Shornikova AV, Casas IA, Mykkanen H, et al. Bacteriotherapy with Lactobacillus reuteri in rotavirus gastroenteritis. Pediatr Infect Dis J. 1997;16:1103-1107.
57. Makelainen H, Tahvonen R, Salminen S, et al. In vivo safety assessment of two Bifidobacterium longum strains. Microbiol Immunol. 2003;47: 911-914.
58. Jiang T, Mustapha A, Savaiano DA. Improvement of lactose digestion in humans by ingestion of unfermented milk containing Bifidobacterium longum. J Dairy Sci. 1996;79:750-757.
59. Korschunov VM, Smeyanov VV, Efimov BA, et al. Therapeutic use of an antibiotic-resistant Bifidobacterium preparation in men exposed to high-dose gamma-irradiation. J Med Microbiol. 1996;44:70-74.
60. Bartram HP, Scheppach W, Gerlach S, et al. Does yogurt enriched with Bifidobacterium longum affect colonic microbiology and fecal metabolites in health subjects? Am J Clin Nutr. 1994;59:428-432.
61. Colombel JF, Cortot A, Neut C, et al. Yoghurt with Bifidobacterium longum reduces erythromycin-induced gastrointestinal effects. Lancet. 1987;2:43.
62. Gill HS, Rutherford KJ, Cross ML, et al. Enhancement of immunity in the elderly by dietary supplementation with the probiotic Bifidobacterium lactis HN019. Am J Clin Nutr. 2001;74:833-839.
63. Isolauri E, Arvola T, Sutas Y, et al. Probiotics in the management of atopic eczema. Clin Exp Allergy. 2000;30:1604-1610.
64. Kirjavainen PV, Arvola T, Salminen SJ, et al. Aberrant composition of gut microbiota of allergic infants: a target of bifidobacterial therapy at weaning? Gut. 2002;51:51-55.
65. Satokari RM, Vaughan EE, Akkermans AD, et al. Polymerase chain reaction and denaturing gradient gel electrophoresis monitoring of fecal bifidobacterium populations in a prebiotic and probiotic feeding trial. Syst Appl Microbiol. 2001;24:227-231.
66. Arunachalam K, Gill HS, Chandra RK. Enhancement of natural immune function by dietary consumption of Bifidobacterium lactis (HN019). Eur J Clin Nutr. 2000;54:263-267.
67. Chiang BL, Sheih YH, Wang LH, et al. Enhancing immunity by dietary consumption of a probiotic lactic acid bacterium (Bifidobacterium lactis HN019): optimization and definition of cellular immune responses. Eur J Clin Nutr. 2000;54:849-855.
68. Gill HS, Rutherfurd KJ, Cross ML. Dietary probiotic supplementation enhances natural killer cell activity in the elderly: an investigation of age-related immunological changes. J Clin Immunol. 2001;21:264-271.
69. Muller J, Remus N, Harms KH. Mycoserological study of the treatment of paediatric cystic fibrosis patients with Saccharomyces boulardii (Saccharomyces cerevisiae Hansen CBS 5926). Mycoses. 1995;38: 119-123.
70. Mansour-Ghanaei F, Dehbashi N, Yazdanparast K, et al. Efficacy of saccharomyces boulardii with antibiotics in acute amoebiasis. World J Gastroenterol. 2003;9:1832-1833.
71. Guslandi M, Giollo P, Testoni PA. A pilot trial of Saccharomyces boulardii in ulcerative colitis. Eur J Gastroenterol Hepatol. 2003;15: 697-698.
72. Cremonini F, Di Caro S, Covino M, et al. Effect of different probiotic preparations on anti-helicobacter pylori therapy-related side effects: a parallel group, triple blind, placebo-controlled study. Am J Gastroenterol. 2002;97:2744-2749.
73. Surawicz CM, McFarland LV, Greenberg RN, et al. The search for a better treatment for recurrent Clostridium difficile disease: use of high-dose vancomycin combined with Saccharomyces boulardii. Clin Infect Dis. 2000;31:1012-1017. Epub 2000 Oct 25.
74. Elmer GW, McFarland LV, Surawicz CM, et al. Behaviour of Saccharomyces boulardii in recurrent Clostridium difficile disease patients. Aliment Pharmacol Ther. 1999;13:1663-1668.
75. Attar A, Flourie B, Rambaud JC, et al. Antibiotic efficacy in small intestinal bacterial overgrowth-related chronic diarrhea: a crossover, randomized trial. Gastroenterology. 1999;117:794-797.
76. Lewis SJ, Potts LF, Barry RE. The lack of therapeutic effect of Saccharomyces boulardii in the prevention of antibiotic-related diarrhoea in elderly patients. J Infect. 1998;36:171-174.
77. Bleichner G, Blehaut H, Mentec H, et al. Saccharomyces boulardii prevents diarrhea in critically ill tube-fed patients: a multicenter, randomized, double-blind placebo-controlled trial. Intensive Care Med. 1997;23:517-523.
78. McFarland LV, Surawicz CM, Greenberg RN, et al. A randomized placebo-controlled trial of Saccharomyces boulardii in combination with standard antibiotics for Clostridium difficile disease. JAMA. 1994;271: 1913-1918 .
79. Erratum in JAMA. 1994;272:518.
80. Surawicz CM, McFarland LV, Elmer G, et al. Treatment of recurrent Clostridium difficile colitis with vancomycin and Saccharomyces boulardii. Am J Gastroenterol. 1989;84:1285-1287.
81. McFarland LV, Surawicz CM, Greenberg RN, et al. Prevention of beta-lactam-associated diarrhea by Saccharomyces boulardii compared with placebo. Am J Gastroenterol. 1995;90:439-448.
82. Surawicz CM, Elmer GW, Speelman P, et al. Prevention of antibiotic-associated diarrhea by Saccharomyces boulardii: a prospective study. Gastroenterology. 1989;96:981-988.
83. Plein K, Hotz J. Therapeutic effects of Saccharomyces boulardii on mild residual symptoms in a stable phase of Crohn's disease with special respect to chronic diarrhea: a pilot study. Z Gastroenterol. 1993;31:129-134.
84. Guslandi M, Mezzi G, Sorghi M, et al. Saccharomyces boulardii in maintenance treatment of Crohn's disease. Dig Dis Sci. 2000;45:1462-1464.
85. Kaila M, Isolauri E, Saxelin M, et al. Viable versus inactivated Lactobacillus GG in acute rotavirus diarrhea. Arch Dis Child. 1995;72: 51-53.
86. Ling WH, Hanninen O, Mykkanen H, et al. Colonization and fecal enzyme activities after oral Lactobacillus GG administration in elderly nursing home residents. Ann Nutr Metab. 1992;36:162-166.
87. Gupta P, Andrew H, Kirschner BS, et al. Is lactobacillus GG helpful in children with Crohn's disease? Results of a preliminary, open-label study. J Pediatr Gastroenterol Nutr. 2000;31:453-457.
88. O'Sullivan MA, O'Morain CA. Bacterial supplementation in the irritable bowel syndrome: a randomized double-blind placebo-controlled crossover study. Dig Liver Dis. 2000;32:294-301.
89. Thomas MR, Litin SC, Osmon DR, et al Lack of effect of Lactobacillus GG on antibiotic-associated diarrhea: a randomized, placebo-controlled trial. Mayo Clin Proc. 2001;76:883-889.
90. Vanderhoof JA, Whitney DB, Antonson DL, et al. Lactobacillus GG in the prevention of antibiotic associated diarrhea in children. J Pediatr. 1999;135:564-568.
91. Guarino A, Canani RB, Spagnuolo MI, et al. Oral bacterial therapy reduces the duration of symptoms and of viral excretion in children with mild diarrhea. J Pediatr Gastroenterol Nutr. 1997;25:516-519.
92. Raza S, Graham SM, Allen SJ, et al. Lactobacillus GG promotes recovery from acute nonbloody diarrhea in Pakistan. Pediatr Infect Dis J. 1995;14:107-111.
93. Isolauri E, Joensuu J, Suomalainen H, et al. Improved immunogenicity of oral D × RRV reassortant rotavirus vaccine by Lactobacillus casei GG. Vaccine. 1995;13:310-312.
94. Majamaa H, Isolauri E, Saxelin M, et al. Lactic acid bacteria in the treatment of acute rotavirus gastroenteritis. J Pediatr Gastroenterol Nutr. 1995;20:333-338.
95. Kaila M, Isolauri E, Saxelin M, et at. Viable versus inactivated lactobacillus strain GG in acute rotavirus diarrhoea. Arch Dis Child. 1995;72:51-53.
96. Stansbridge EM, Walker V, Hall MA, et al. Effects of feeding premature infants with Lactobacillus GG on gut fermentation. Arch Dis Child. 1993;69:488-492.
97. Millar MR, Bacon C, Smith SL, et al. Enteral feeding of premature infants with Lactobacillus GG. Arch Dis Child. 1993;69:483-487.
98. Isolauri E, Juntunen M, Rautanen T, et al. A human Lactobacillus strain (Lactobacillus casei sp strain GG) promotes recovery from acute diarrhea in children. Pediatrics. 1991;88:90-97.
99. Colodner R, Edelstein H, Chazan B, et al. Vaginal colonization by orally administered Lactobacillus rhamnosus GG. Isr Med Assoc J. 2003;5: 767-769.
100. Hatakka K, Martio J, Korpela M, et al. Effects of probiotic therapy on the activity and activation of mild rheumatoid arthritis: a pilot study. Scand J Rheumatol. 2003;32:211-215.
101. Kuisma J, Mentula S, Jarvinen H, et al. Effect of Lactobacillus rhamnosus GG on ileal pouch inflammation and microbial flora. Aliment Pharmacol Ther. 2003;17:509-515.
102. Prantera C, Scribano ML. Probiotics and Crohn's disease. Dig Liver Dis. 2002;34(suppl 2):66-67.
103. Nase L, Hatakka K, Savilahti E, et al. Effect of long-term consumption of a probiotic bacterium, Lactobacillus rhamnosus GG, in milk on dental caries and caries risk in children. Caries Res. 2001;35:412-420.
104. Reid G, Beuerman D, Heinemann C, et al. Probiotic Lactobacillus dose required to restore and maintain a normal vaginal flora. FEMS Imnmnol Med Microbiol. 2001;32:37-41.
105. Pochapin M. The effect of probiotics on Clostridium difficile diarrhea. Am J Gastroenterol. 2000;95(suppl 1):11-13.
106. Pessi T, Sutas Y, Hurme M, et al. Interleukin-10 generation in atopic children following oral Lactobacillus rhamnosus GG. Clin Exp Allergy. 2000;30:1804-1808.
107. Arvola T, Laiho K, Torkkeli S, et al. Prophylactic Lactobacillus GG reduces antibiotic-associated diarrhea in children with respiratory infections: a randomized study. Pediatrics. 1999;104:e64.
108. Sakamoto I, Igarashi M, Kimura K, et al. Suppressive effect of Lactobacillus gasseri OLL 2716 (LG21) on Helicobacter pylori infection in humans. J Antimicrob Chemother. 2001;47:709-710.
109. Pedrosa MC, Golner BB, Goldin BR, et al. Survival of yogurt-containing organisms and Lactobacillus gasseri (ADH) and their effect on bacterial enzyme activity in the gastrointestinal tract of healthy and hypochlorhydric elderly subjects. Am J Clin Nutr. 1995;61:353-359.
110. Cruchet S, Obregon MC, Salazar G, et al. Effect of the ingestion of a dietary product containing Lactobacillus johnsonii La1 on Helicobacter pylori colonization in children. Nutrition. 2003;19:716-721.
111. Felley CP, Corthesy-Theulaz I, Rivero JL, et al. Favourable effect of an acidified milk (LC-1) on Helicobacter pylori gastritis in man. Eur J Gastroenterol Hepatol. 2001;13:25-29.
112. Michetti P, Dorta G, Wiesel PH, et al. Effect of whey-based culture supernatant of Lactobacillus acidophilus (johnsonii) La1 on Helicobacter pylori infection in humans. Digestion. 1999;60:203-209.
113. de Roos NM, Schonten G, Katan MB. Yoghurt enriched with Lactobacillus acidophilus does not lower blood lipids in healthy men and women with normal to borderline high serum cholesterol levels. Eur J Clin Nutr. 1999;53:277-280.
114. Pantoflickova D, Corthesy-Theulaz I, Dorta G, et al. Favourable effect of regular intake of fermented milk containing Lactobacillus johnsonii on Helicobacter pylori associated gastritis. Aliment Pharmacol Ther. 2003; 18:805-813.
115. Schiffrin EJ, Brassart D, Servin AL, et al. Immune modulation of blood leukocytes in humans by lactic acid bacteria: criteria for strain selection. Am J Clin Nutr. 1997;66:515S-520S.
116. Marteau P, Vaerman JP, Dehennin JP, et al. Effects of intrajejunal perfusion and chronic ingestion of Lactobacillus johnsonii strain La1 on serum concentrations and jejunal secretions of immunoglobulins and serum proteins in healthy humans. Gastroenterol Clin Biol. 1997;21:293-298.
117. Gotteland M, Cruchet S. Suppressive effect of frequent ingestion of Lactobacillus johnsonii La1 on Helicobacter pylori colonization in asymptomatic volunteers. J Antimicrob Chemother. 2003;51:1317-1319. Epub 2003 Apr 14.
118. Bahijiri SM, Mira SA, Mufti AM, et al. The effects of inorganic chromium and brewer's yeast supplementation on glucose tolerance, serum lipids and drug dosage in individuals with type 2 diabetes. Saudi Med. J. 2000;21:831-837.
119. Facchinetti F, Nappi RE, Sances MG, et al. Effects of a yeast-based dietary supplementation on premenstrual syndrome: a double-blind placebo-controlled study. Gynecol Obstet Invest. 1997;43:120-124.
120. Barclay GR, McKenzie H, Pennington J, et al. The effect of dietary yeast on the activity of stable chronic Crohn's disease. Scand J Gastroenterol. 1992;27:196-200.
121. Scevola D, Perversi L, Cavanna C, et al. Acid tolerance and fecal recovery following oral administration of Saccharomyces cerevisiae. J Chemother. 2003;15:143-147.
122. Li YC. Effects of brewer's yeast on glucose tolerance and serum lipids in Chinese adults. Biol Trace Elem Res. 1994;41:341-347.
123. Frank DH, Roe DJ, Chow HH, et al. Effects of a high-selenium yeast supplement on celecoxib plasma levels: a randomized phase II trial. Cancer Epidemiol Biomarkers Prev. 2004;13:299-303.
124. Wenk R, Bertolino M, Ochoa J, et al. Laxative effects of fresh baker's yeast. J Pain Symptom Manage. 2000;19:163-164.
125. Marteau P, Cuillerier E, Meance S, et al. Bifidobacterium animalis strain DN-173 010 shortens the colonic transit time in healthy women: a double-blind, randomized, controlled study. Aliment Pharmacol Ther. 2002;16:587-593.
126. Donnet-Hughes A, Rochat F, Serrant P, et al. Modulation of nonspecific mechanisms of defense by lactic acid bacteria effective dose. J Dairy Sci. 1999;82:863-869.
127. Di Marzio L, Centi C, Cinque B, et al. Effect of the lactic acid bacterium Streptococcus thermophilus on stratum corneum ceramide levels and signs and symptoms of atopic dermatitis patients. Exp Dermatol. 2003; 12:615-620.
128. Di Marzio L, Cinque B, De Simone C, et al. Effect of the lactic acid bacterium Streptococcus thermophilus on ceramide levels in human keratinocytes in vitro and stratum corneum in vivo. J Invest Dermatol. 1999;113:98-106.
129. Sudarmo SM, Ranuh RG, Rochim A, et al. Management of infant diarrhea with high-lactose probiotic-containing formula. Southeast Asian J Trop Med Public Health. 2003;34:845-848.
130. Nopchinda S, Varavithya W, Phuapradit P, et al. Effect of bifidobacterium Bb12 with or without Streptococcus thermophilus supplemented formula on nutritional status. J Med Assoc Thai. 2002;85(suppl 4):1225-1231.
131. Langhendries JP, Detry J, Van Hees J, et al. Effect of a fermented infant formula containing viable bifidobacteria on the fecal flora composition and pH of healthy full-term infants. J Pediatr Gastroenterol Nutr. 1995; 21:177-181.
132. Phuapradit P, Varavithya W, Vathanophas K, et al. Reduction of rotavirus infection in children receiving bifidobacteria-supplemented formula. J Med Assoc Thai. 1999;82(suppl 1):43-48.
133. Vesa TH, Marteau P, Zidi S, et al. Digestion and tolerance of lactose from yoghurt and different semi-solid fermented dairy products containing Lactobacillus acidophilus and bifidobacteria in lactose maldigesters: is bacterial lactase important? Eur J Clin Nutr. 1996;50:730-733.
134. Loguercio C, Del Vecchio Blanco C, Coltorti M. Enterococcus lactic acid bacteria strain SF68 and lactulose in hepatic encephalopathy: a controlled study. J Int Med Res. 1987;15:335-343.
135. Lund B, Edlund C, Barkholt L, et al. Impact on human intestinal microflora of an Enterococcus faecium probiotic and vancomycin. Scand J Infect Dis. 2000;32:627-632.
136. Lund B, Adamsson I, Edlund C. Gastrointestinal transit survival of an Enterococcus faecium probiotic strain administered with or without vancomycin. Int J Food Microbiol. 2002;77:109-115.
137. Urbancsek H, Kazar T, Mezes I, et al. Results of a double-blind, randomized study to evaluate the efficacy and safety of Antibiophilus in patients with radiation-induced diarrhoea. Eur J Gastroenterol Hepatol. 2001;13:391-396.
138. Helin T, Haahtela S, Haahtela T. No effect of oral treatment with an intestinal bacterial strain, Lactobacillus rhamnosus (ATCC 53103), on birch-pollen allergy: a placebo-controlled double-blind study. Allergy. 2002;57:243-246.
139. Sheih YH, Chiang BL, Wang LH, et al. Systemic immunity-enhancing effects in healthy subjects following dietary consumption of the lactic acid bacterium Lactobacillus rhamnosus HN001. J Am Coll Nutr. 2001; 20(suppl 2)149-156.
140. Shimakawa Y, Matsubara S, Yuki N, et al. Evaluation of Bifidobacterium breve strain Yakult-fermented soymilk as a probiotic food. Int J Food Microbiol. 2003;81:131-136.
141. Kitajima H, Sumida Y, Tanaka R, et al. Early administration of Bifidobacterium breve to preterm infants: randomized controlled trial. Arch Dis Child Fetal Neonatal Ed. 1997;76:F101-F107.
142. Lee MC, Lin LH, Hung KL, et al. Oral bacterial therapy promotes recovery from acute diarrhea in children. Acta Paediatr Taiwan. 2001; 42:301-305.
143. Hoyos AB. Reduced incidence of necrotizing enterocolitis associated with enteral administration of Lactobacillus acidophilus and Bifidobacterium infantis to neonates in an intensive care unit. Int J Infect Dis. 1999;3:197-202.
144. Campieri C, Campieri M, Bertuzzi V, et al. Reduction of oxaluria after an oral course of lactic acid bacteria at high concentration. Kidney Int. 2001; 60:1097-1105.
145. Kiessling G, Schneider J, Jahreis G. Long-term consumption of fermented dairy products over 6 months increases HDL cholesterol. Eur J Clin Nutr. 2002;56:843-849.
146. Agarwal KN, Bhasin SK. Feasibility studies to control acute diarrhoea in children by feeding fermented milk preparations Actimel and Indian Dahi. Eur J Clin Nutr. 2002;56(suppl 4):56-59.
147. Gaon D, Garcia H, Winter L, et al. Effect of Lactobacillus strains and Saccharomyces boulardii on persistent diarrhea in children. Medicina (B Aires). 2003;63:293-298.
148. Gaon D, Garmendia C, Murrielo NO, et al. Effect of Lactobacillus strains (L. casei and L. Acidophillus Strains cerela) on bacterial overgrowth-related chronic diarrhea. Medicina (B Aires). 2002;62:159-163.
149. Laake KO, Line PD, Aabakken L, et al. Assessment of mucosal inflammation and circulation in response to probiotics inpatients operated with ileal pouch anal anastomosis for ulcerative colitis. Scand J Gastroenterol. 2003;38:409-414.
150. Ishikawa H, Akedo I, Umesaki Y, et al. Randomized controlled trial of the effect of bifidobacteria-fermented milk on ulcerative colitis. J Am Coll Nutr. 2003;22:56-63.
151. Gionchetti P, Rizzello F, Helwig U, et al. Prophylaxis of pouchitis onset with probiotic therapy: a double-blind, placebo-controlled trial. Gastroenterology. 2003;124:1202-1209.
152. Venturi A, Gionchetti P, Rizzello F, et al. Impact on the composition of the faecal flora by a new probiotic preparation: preliminary data on maintenance treatment of patients with ulcerative colitis. Aliment Pharmacol Ther. 1999;13:1103-1108.
153. Kim HJ, Camilleri M, McKinzie S, et al. A randomized controlled trial of a probiotic, VSL#3, on gut transit and symptoms in diarrhoea-predominant irritable bowel syndrome. Aliment Pharmacol Ther. 2003;17: 895-904.
154. Delia P, Sansotta G, Donate V, et al. Prevention of radiation-induced diarrhea with the use of VSL#3, a new high-potency probiotic preparation. Am J Gastroenterol. 2002;97:2150-2152.
155. Mimura T, Rizzello F, Helwig U, et al. Once daily high dose probiotic therapy (VSL#3) for maintaining remission in recurrent or refractory pouchitis. Gut. 2004;53:108-114.
156. Anderson AD, McNaught CE, Jain PK, et al. Randomised clinical trial of synbiotic therapy in elective surgical patients. Gut. 2004;53:241-245. Epub 2003 Jul 15.
157. Sullivan A, Barkholt L, Nord CE. Lactobacillus acidophilus, Bifidobacterium lactis and Lactobacillus F19 prevent antibiotic-associated ecological disturbances of Bacteroides fragilis in the intestine. J Antimicrob Chemother. 2003;52:308-311.
158. Gluck U, Gebbers JO. Ingested probiotics reduce nasal colonization with pathogenic bacteria (Staphylococcus aureus, Streptococcus pneumoniae, and beta-hemolytic streptococci). Am J Clin Nutr. 2003;77:517-520.
159. Orrhage K, Sjostedt S, Nord CE. Effect of supplements with lactic acid bacteria and oligofructose on the intestinal microflora during administration of cefpodoxime proxetil. J Antimicrob Chemother. 2000;46: 603-612.
160. Agerholm-Larsen L, Raben A, Haulrik N, et al. Effect of 8 week intake of probiotic milk products on risk factors for cardiovascular diseases. Eur J Clin Nutr. 2000;54:288-297.
161. Nielsen OH, Jorgensen S, Pedersen K, et al. Microbiological evaluation of jejunal aspirates and faecal samples after oral administration of bifidobacteria and lactic acid bacteria. J Appl Bacteriol. 1994;76:469-474.
162. Gonzalez SN, Cardozo R, Apella MC, et al. Biotherapeutic role of fermented milk. Biotherapy. 1994;8:129-134.
163. De Simone C, Ciardi A, Grassi A, et al. Effect of Bifidobacterium bifidum and Lactobacillus acidophilus on gut mucosa and peripheral blood B lymphocytes. Immunopharmacol Immunotoxicol. 1992;14: 331-340.
164. Black F, Einarsson K, Lidbeck A, et al. Effect of lactic acid producing bacteria on the human intestinal microflora during ampicillin treatment. Scand J Infect Dis. 1991;23:247-254.
165. Tankanow RM, Ross MB, Ertel IJ, et al. A double-blind, placebo-controlled study of the efficacy of Lactinex in the prophylaxis of amoxicillin-induced diarrhea. DICP. 1990;24:382-384.
166. Lin SY, Ayres JW, Winkler W Jr, et al. Lactobacillus effects on cholesterol: in vitro and in vivo results. J Dairy Sci. 1989;72:2885-2899.
167. Clements ML, Levine MM, Black RE, et al. Lactobacillus prophylaxis for diarrhea due to enterotoxigenic Escherichia coli. Antimicrob Agents Chemother. 1981;20:104-108.
168. Agarwal KN, Bhasin SK, Faridi MM, et al. Lactobacillus casei in the control of acute diarrhea: a pilot study. Indian Pediatr. 2001;38: 905-910.
169. Kawase M, Hashimoto H, Hosoda M, et al. Effect of administration of
170. Rosenfeldt V, Benfeldt E, Nielsen SD, et al. Effect of probiotic Lactobacillus strains in children with atopic dermatitis. Allergy Clin Immunol. 2003;111:389-395.
171. Rosenfeldt V, Michaelsen KF, Jakobsen M, et al. Effect of probiotic Lactobacillus strains on acute diarrhea in a cohort of nonhospitalized children attending day-care centers. Pediatr Infect Dis J. 2002;21: 417-419.
172. Rosenfeldt V, Michaelsen KF, Jakobsen M, et al. Effect of probiotic Lactobacillus strains in young children hospitalized with acute diarrhea. Pediatr Infect Dis J. 2002;21:411-416.
173. Jacobsen CN, Rosenfeldt Nielsen V, Hayford AE, et al. Screening of probiotic activities of forty-seven strains of Lactobacillus spp. by in vitro techniques and evaluation of the colonization ability of five selected strains in humans. Appl Environ Microbiol. 1999;65:4949-4956.
174. Reid G, Charbonneau D, Erb J, et al. Oral use of Lactobacillus rhamnosus GR-1 and L. fermentum RC-14 significantly alters vaginal flora: randomized, placebo controlled trial in 64 healthy women. FEMS Immunol Med Microbiol. 2003;35:131-134.
175. Ahola AJ, Yli-Knuuttila H, Suomalainen T, et al. Short-term consumption of probiotic-containing cheese and its effect on dental caries risk factors. Arch Oral Biol. 2002;47:799-804.
176. Wheeler JG, Shema SJ, Bogle ML, et al. Immune and clinical impact of Lactobacillus acidophilus on asthma. Ann Allergy Asthma Immunol. 1997;79:229-233.
177. Witsell DL, Garrett CG, Yarbrough WG, et al. Effect of Lactobacillus acidophilus on antibiotic-associated gastrointestinal morbidity: a prospective randomized trial. J Otolaryngol. 1995;24:230-233.
178. Saavedra JM, Bauman NA, Oung I, et al. Feeding of Bifidobacterium bifidum and Streptococcus thermophilus to infants in hospital for prevention of diarrhoea and shedding of rotavirus. Lancet. 1994;344:1046-1049.
179. Nielsen OH, Jorgensen S, Pedersen K, et al. Microbiological evaluation of jejunal aspirates and faecal samples after oral administration of bifidobacteria and lactic acid bacteria. J Appl Bacterial. 1994;76: 469-474.
180. De Simone C, Ciardi A, Grassi A, et al. Effect of Bifidobacterium bifidum and Lactobacillus acidophilus on gut mucosa and peripheral blood B lymphocytes. Immunopharmacol Immunotoxicol. 1992;14:331-340.
181. Black F, Einarsson K, Lidbeck A, et al. Effect of lactic acid producing bacteria on the human intestinal microflora during ampicillin treatment. Scand J Infect Dis. 1991;23:247-254.
182. Orrhage K, Sjostedt S, Nord CE. Effect of supplements with lactic acid bacteria and oligofructose on the intestinal microflora during administration of cefpodoxime proxetil. J Antimicrob Chemother. 2000;46:603-612.
183. Richelsen B, Kristensen K, Pedersen SB. Long-term (6 months) effect of a new fermented milk product on the level of plasma lipoproteins: a placebo-controlled and double blind study. Eur J Clin Nutr. 1996;50:811-815.
184. Agerbaek M, Gerdes LU, Richelsen B. Hypocholesterolaemic effect of a new fermented milk product in healthy middle-aged men. Eur J Clin Nutr. 1995;49:346-352.
185. Saavedra JM, Abi-Hartna A, Moore N, et al. Long-term consumption of infant formulas containing live probiotic bacteria: tolerance and safety. Am J Clin Nutr. 2004;79:261-267.
186. Boudraa G, Benbouabdellah M, Hachelaf W, et al. Effect of feeding yogurt versus milk in children with acute diarrhea and carbohydrate malabsorption. J Pediatr Gastroenterol Nutr. 2001;33:307-313.
187. Petti S, Tarsitani G, D'Arca AS. A randomized clinical trial of the effect of yoghurt on the human salivary microflora. Arch Oral Biol. 2001;46: 705-712.
188. Rizkalla SW, Luo J, Kabir M, et al. Chronic consumption of fresh but not heated yogurt improves breath-hydrogen status and short-chain fatty acid profiles: a controlled study in healthy men with or without lactose maldigestion. Am J Clin Nutr. 2000;72:1474-1479.
189. Hata Y, Yamamoto M, Ohni M, et al. A placebo-controlled study of the effect of sour milk on blood pressure in hypenensive subjects. Am J Clin Nutr. 1996;64:767-771.
190. Pedone CA, Arnaud CC, Postaire ER, et al. Multicentric study of the effect of milk fermented by Lactobacillus casei on the incidence of diarrhoea. Int J Clin Pract. 2000;54:568-571.
191. Xiao JZ, Kondo S, Takahashi N, et al. Effects of milk products fermented by Bifidobacterium longum on blood lipids in rats and healthy adult male volunteers. J Dairy Sci. 2003;86:2452-2461.